FGAM
MACK

Financial Gravity Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Financial Gravity Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$0 Hold
4
– – ﹤0.01% 1734
2018
Q2 		$0 Hold
4
– – ﹤0.01% 1736
2018
Q1 		$0 Buy
+4
New +$33 ﹤0.01% 1570

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Financial Gravity Asset Management's MACK Position: Q3 2018 in Review

Financial Gravity Asset Management held its Merrimack Pharmaceuticals, Inc. (MACK) position steady in Q3 2018 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Financial Gravity Asset Management first reported a position in MACK in Q1 2018 and has held it in 3 quarters since. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • Financial Gravity Asset Management held 4 shares of Merrimack Pharmaceuticals, Inc. worth $0 as of Q3 2018.
  • Financial Gravity Asset Management left its Merrimack Pharmaceuticals, Inc. share count unchanged in Q3 2018.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q3 2018, its #1734 holding.
  • Financial Gravity Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2018 and has held it in 3 quarters since.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Financial Gravity Asset Management's 13F filing for Q3 2018, filed 31 Oct 2018.